Moonmoon Kazi/LinkedIn
Jun 15, 2026, 12:46
Moonmoon Kazi: Climb Bio Presents Phase 1b ITP Trial Data at EHA 2026
Moonmoon Kazi, Sr. Medical Director at Climb Bio, shared a post on LinkedIn:
“It has been six months into my role at Climb Bio and I’m so grateful to be part of an organization with a clear, science‑driven vision for building a focused and differentiated pipeline.
Presenting preliminary data from our Phase 1b ITP trial was a meaningful milestone, reinforcing how thoughtful translational strategy and rigorous early clinical execution inform downstream pipeline decisions.
I’m energized by the clarity of purpose and the caliber of the team, and I look forward to helping advance programs with the potential to meaningfully impact patients.”
Stay updated with Hemostasis Today.
-
Sep 29, 2026, 19:00Caitlin Raymond: Can Artificial Blood Solve Blood Supply Shortages?
-
Sep 29, 2026, 18:51Chaza Alaji: Dyslipidemia, Thrombosis and the DIC Diagnostic Trap
-
Sep 29, 2026, 17:31Rajnikant Patel: Bridging Ayurvedic Concepts and Modern Toxin-Mediated Disease
-
Sep 29, 2026, 17:13Nicholas Lang։ A Meaningful Case of Immune Thrombocytopenia
-
Sep 29, 2026, 16:55Ayatullah Gamal Wahab: When the CBC Lies
-
Sep 29, 2026, 16:35Jonathan Douxfils: Navigating the VTE Risk Continuum in Reproductive Medicine
-
Sep 29, 2026, 16:35Chaima Rajeh: Types of Anemia and Their Laboratory Features
-
Sep 29, 2026, 16:27Scott Isaacs: How GLP-1 RAs Target Systemic Inflammation to Drive Cardio, Autoimmune, and Gut Health
-
Sep 29, 2026, 16:21Yitshak Kreiss: From Treating Patients to Defining the Standard of Knowledge